Stock AnalizGenmab A GMAB
Biotechnology: Pharmaceutical Preparations · IPO 2019 · data as of November 13, 2026
Genmab A (GMAB) is a healthcare company listed in the US with a market value of about $32.1B. In the twelve months to September 30, 2026 it had revenue of $4.3B and net income of $729M, a net margin of 17.0%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is track record (3/5); the weakest is value (1/5).
Key numbers: a P/E of 44.0, a price to free cash flow of 38.0, 5-year revenue growth of 58% a year, a 5-year average ROIC of 12%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 35% above the current price.
Score: 2.0 / 5
Checks passed
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
- ROE above 15%
- Positive free cash flow
- Interest covered more than 5 times
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | $4.3B | $3.7B | $3.1B | $2.4B | $807M | $464M | $381M |
| Net income | $729M | $963M | $1.1B | $631M | — | — | — |
| Free cash flow | $843M | $1.1B | $1.1B | $1.0B | — | — | — |
| EPS (diluted) | $1.17 | $1.54 | $1.82 | $1.01 | — | — | — |
| Net margin | 17.0% | 25.9% | 36.3% | 26.4% | — | — | — |
| ROIC | — | 7.7% | 16.2% | 12.7% | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $65.01, 27% above the current price; targets range from $48.00 to $80.00; the consensus rating is “Strong buy”; expected EPS is $1.26 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Genmab A’s P/E ratio?
About 44.0, based on the last twelve months of diluted earnings per share (forward P/E about 37.5).
Is Genmab A stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 35% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Genmab A pay a dividend?
Not currently.
Is Genmab A a good stock to buy?
We do not give buy or sell advice. Genmab A scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.